These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12912859)

  • 1. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study.
    Nikolaus S; Rutgeerts P; Fedorak R; Steinhart AH; Wild GE; Theuer D; Möhrle J; Schreiber S
    Gut; 2003 Sep; 52(9):1286-90. PubMed ID: 12912859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis.
    Pena-Rossi C; Schreiber S; Golubovic G; Mertz-Nielsen A; Panes J; Rachmilewitz D; Shieh MJ; Simanenkov VI; Stanton D; Graffner H
    Aliment Pharmacol Ther; 2008 Sep; 28(6):758-67. PubMed ID: 19145731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial.
    Musch E; Andus T; Kruis W; Raedler A; Spehlmann M; Schreiber S; Krakamp B; Malek M; Malchow H; Zavada F; Engelberg Feurle G
    Clin Gastroenterol Hepatol; 2005 Jun; 3(6):581-6. PubMed ID: 15952100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study.
    Pena Rossi C; Hanauer SB; Tomasevic R; Hunter JO; Shafran I; Graffner H
    BMC Gastroenterol; 2009 Mar; 9():22. PubMed ID: 19302707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial.
    Musch E; Andus T; Malek M
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1233-9. PubMed ID: 12144572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.
    Andersen O; Elovaara I; Färkkilä M; Hansen HJ; Mellgren SI; Myhr KM; Sandberg-Wollheim M; Soelberg Sørensen P
    J Neurol Neurosurg Psychiatry; 2004 May; 75(5):706-10. PubMed ID: 15090564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
    Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a.
    Schott E; Paul F; Wuerfel JT; Zipp F; Rudolph B; Wiedenmann B; Baumgart DC
    World J Gastroenterol; 2007 Jul; 13(26):3638-40. PubMed ID: 17659718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
    Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
    Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.
    Francis GS; Grumser Y; Alteri E; Micaleff A; O'Brien F; Alsop J; Stam Moraga M; Kaplowitz N
    Drug Saf; 2003; 26(11):815-27. PubMed ID: 12908850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type I interferons for induction of remission in ulcerative colitis.
    Seow CH; Benchimol EI; Griffiths AM; Steinhart AH
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006790. PubMed ID: 18646167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
    De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C
    J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study.
    Gold R; Rieckmann P; Chang P; Abdalla J;
    Eur J Neurol; 2005 Aug; 12(8):649-56. PubMed ID: 16053475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta--an open long-term trial.
    Musch E; Andus T; Malek M; Chrissafidou A; Schulz M
    Z Gastroenterol; 2007 Dec; 45(12):1235-40. PubMed ID: 18080224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis.
    Rieckmann P; O'Connor P; Francis GS; Wetherill G; Alteri E
    Drug Saf; 2004; 27(10):745-56. PubMed ID: 15350158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.